These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 25687498)

  • 1. Changes in serum alanine aminotransferase levels in telbivudine versus lamivudine treatment for chronic hepatitis B: a meta-analysis.
    Dai M; Xiao GM; Wang FL; Zhang JS; Li YM; Yang HZ
    J Int Med Res; 2015 Apr; 43(2):161-72. PubMed ID: 25687498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Telbivudine versus lamivudine and entecavir for treatment-naïve decompensated hepatitis B virus-related cirrhosis.
    Yue-Meng W; Li YH; Wu HM; Yang J; Xu Y; Yang LH; Yang JH
    Clin Exp Med; 2017 May; 17(2):233-241. PubMed ID: 27094312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B.
    Liaw YF; Gane E; Leung N; Zeuzem S; Wang Y; Lai CL; Heathcote EJ; Manns M; Bzowej N; Niu J; Han SH; Hwang SG; Cakaloglu Y; Tong MJ; Papatheodoridis G; Chen Y; Brown NA; Albanis E; Galil K; Naoumov NV;
    Gastroenterology; 2009 Feb; 136(2):486-95. PubMed ID: 19027013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.
    Pellicelli AM; Barbaro G; Francavilla R; Romano M; Barbarini G; Mazzoni E; Mecenate F; Paffetti A; Barlattani A; Struglia C; Villani R; Nauri L; Nosotti L; Armignacco O; Ferri F; Camporiondo MP; Soccorsi F;
    Clin Ther; 2008 Feb; 30(2):317-23. PubMed ID: 18343270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: a 4-year study.
    Vassiliadis TG; Giouleme O; Koumerkeridis G; Koumaras H; Tziomalos K; Patsiaoura K; Grammatikos N; Mpoumponaris A; Gkisakis D; Theodoropoulos K; Panderi A; Katsinelos P; Eugenidis N
    J Gastroenterol Hepatol; 2010 Jan; 25(1):54-60. PubMed ID: 19780875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of telbivudine versus lamivudine in interrupting perinatal transmission of hepatitis B virus.
    Yu MM; Jiang Q; Ji Y; Wu KH; Ju LL; Tang X; Yang YF
    J Clin Virol; 2014 Sep; 61(1):55-60. PubMed ID: 24994007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lamivudine versus telbivudine in the treatment of chronic hepatitis B: a systematic review and meta-analysis.
    Jiang H; Wang J; Zhao W
    Eur J Clin Microbiol Infect Dis; 2013 Jan; 32(1):11-8. PubMed ID: 22898727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of lamivudine combined with adefovir dipivoxil versus entecavir monotherapy in patients with hepatitis B-associated decompensated cirrhosis: A meta-analysis.
    Peng H; Liu J; Yang M; Tong S; Yin W; Tang H; Hu P; Hu H; Ren H
    J Clin Pharmacol; 2014 Feb; 54(2):189-200. PubMed ID: 24105676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the efficacy of lamivudine and telbivudine in the treatment of chronic hepatitis B: a systematic review.
    Zhao S; Tang L; Fan X; Chen L; Zhou R; Dai X
    Virol J; 2010 Sep; 7():211. PubMed ID: 20815890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone.
    Shim JH; Suh DJ; Kim KM; Lim YS; Lee HC; Chung YH; Lee YS
    Hepatology; 2009 Oct; 50(4):1064-71. PubMed ID: 19637288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial.
    Hou J; Yin YK; Xu D; Tan D; Niu J; Zhou X; Wang Y; Zhu L; He Y; Ren H; Wan M; Chen C; Wu S; Chen Y; Xu J; Wang Q; Wei L; Chao G; Constance BF; Harb G; Brown NA; Jia J
    Hepatology; 2008 Feb; 47(2):447-54. PubMed ID: 18080339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the antiviral effects of different nucleos(t)ide analogues in chinese patients with chronic hepatitis B: a head-to-head study.
    Yu S; Zhou Q; Zhao XM; Yuan M; Wang CT; Cheng XG; Zhang ZH; Li X
    Saudi J Gastroenterol; 2014; 20(6):350-5. PubMed ID: 25434315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum HBV DNA level at week 12 is superior to viral response at week 24 in predicting long-term treatment outcome of telbivudine for chronic hepatitis B patients.
    Lü W; Yang HH; Fan YM; Li T; Zhang LF; Mui C; Fan HW; Zhou BT; Liu ZY; Ng H; Liu XQ
    Chin Med J (Engl); 2013 Jun; 126(12):2333-6. PubMed ID: 23786949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of telbivudine therapy in liver failure patients with chronic hepatitis B virus infection.
    Wang L; Chen H; Fan C; Gong Z
    J Med Virol; 2013 Nov; 85(11):1907-12. PubMed ID: 23852947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Maternal-fetal outcomes of lamivudine treatment administered during late pregnancy to highly viremic mothers with HBeAg+ chronic hepatitis B].
    Jiang HX; Han GR; Wang CM; Ji Y
    Zhonghua Gan Zang Bing Za Zhi; 2012 Dec; 20(12):888-91. PubMed ID: 23522247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients: a randomized, controlled study.
    Sun J; Xie Q; Tan D; Ning Q; Niu J; Bai X; Fan R; Chen S; Cheng J; Yu Y; Wang H; Xu M; Shi G; Wan M; Chen X; Tang H; Sheng J; Dou X; Shi J; Ren H; Wang M; Zhang H; Gao Z; Chen C; Ma H; Jia J; Hou J
    Hepatology; 2014 Apr; 59(4):1283-92. PubMed ID: 24382690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Question of ALT flare during switch to adefovir from lamivudine: A single center open-label, randomized, safety study (June 17, 2005 to February 5, 2009).
    Hann HW; Dunn SR; Ahn M; Park SY
    J Med Virol; 2010 Sep; 82(9):1489-93. PubMed ID: 20648601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching to adefovir monotherapy after emergence of lamivudine-resistant mutations in patients with liver cirrhosis.
    Liaw YF; Lee CM; Chien RN; Yeh CT
    J Viral Hepat; 2006 Apr; 13(4):250-5. PubMed ID: 16611191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Forty-eight-week retrospective study of telbivudine and lamivudine treatment in patients with hepatitis B-related cirrhosis.
    Han Z; Shi Y; Zhu J; Chen Y; Yin F; Xia L; Luo G; Gao Z; Liu J; Jia G; Li C; Zhou X; Han Y
    J Viral Hepat; 2013 Apr; 20 Suppl 1():58-64. PubMed ID: 23458526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Entecavir 1mg versus combined lamivudine/adefovir dipivoxil in chronic HBV Egyptian patients resistant to LAM monotherapy, non-randomised controlled study.
    Maklad S; Doss W; El Din SS; Hassan K; Zeid AA
    Arab J Gastroenterol; 2014 Mar; 15(1):1-5. PubMed ID: 24630505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.